<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111344</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-1002-CU</org_study_id>
    <nct_id>NCT01111344</nct_id>
  </id_info>
  <brief_title>Glizigen-Viudid-External Anogenital Warts in Children and Adolescents</brief_title>
  <official_title>Efficacy of Glizigen-Viudid in the Treatment of External Anogenital Warts in Children and Adolescents.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy of Glizigen and Viusid administration in
      the treatment of external anogenital warts in children and adolescents. The duration of this
      double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number
      of persons to be recruited and randomized for the study is 76. Variables to be assessed will
      be: time to disappearance of lesions, reduction of the number of lesions and change in the
      aspect of lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to lesion regression</measure>
    <time_frame>12 weeks</time_frame>
    <description>Excellent: Lesion regression before 2 weeks of treatment Good: Lesion regression between 2-5 weeks of treatment Poor: Lesion regression between 5-8 weeks of treatment Bad: No lesion regression after 8 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse effects within the 12 week treatment period</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in the number of lesions</measure>
    <time_frame>12 weeks</time_frame>
    <description>Excellent: Regression in more than 75% of lesions Good: Regression in 50-75% of lesions Poor: Regression in 25-50% of lesions Bad: Regression in less than 25% of lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion aspect</measure>
    <time_frame>12 weeks</time_frame>
    <description>Excellent: Lesion regression Poor: Aspect changes from papilloma shaped to flat shaped lesion. Bad: No change in aspect or change from flat shaped to papilloma shaped lesion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>External Anogenital Warts</condition>
  <arm_group>
    <arm_group_label>Glizigen + Viusid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glizigen + Viusid</intervention_name>
    <description>Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).
1 to 3.9 cm2 ______________3 daily applications
4 to 6.9 cm2 ______________4 daily applications
7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.
Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion.</description>
    <arm_group_label>Glizigen + Viusid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).
1 to 3.9 cm2 ______________3 daily applications
4 to 6.9 cm2 ______________4 daily applications
7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.
Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No previous treatment for anogenital warts

          -  Negative serology for HB and HIV.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Pregnancy

          -  Treatment with steroids, immune-suppressors, immune-modulators or local or systemic
             antiviral drugs.

          -  Hypersensitivity to Glizigen or Viusid:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edelisa Moredo Romo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Hospital &quot;Dr. Juan Manuel Márquez.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Hospital &quot;Dr. Juan Manuel Márquez&quot;.</name>
      <address>
        <city>Havana</city>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>May 6, 2012</last_update_submitted>
  <last_update_submitted_qc>May 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dietary supplement</keyword>
  <keyword>Anogenital warts</keyword>
  <keyword>Viusid</keyword>
  <keyword>Glizigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

